Compare MERC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MERC | BMEA |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 98.6M |
| IPO Year | 1987 | 2021 |
| Metric | MERC | BMEA |
|---|---|---|
| Price | $1.72 | $1.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.00 | ★ $8.71 |
| AVG Volume (30 Days) | 592.7K | ★ 1.4M |
| Earning Date | 02-12-2026 | 11-04-2025 |
| Dividend Yield | ★ 8.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,906,971,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $0.87 |
| 52 Week High | $8.28 | $4.23 |
| Indicator | MERC | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 42.06 |
| Support Level | $1.67 | $1.03 |
| Resistance Level | $2.53 | $1.22 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 19.23 | 28.91 |
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.